We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Stealth BioTherapeutics Corporation | NASDAQ:MITO | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.32 | 0.3181 | 0.20 | 0 | 01:00:00 |
As filed with the Securities and Exchange Commission on February 26, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Stealth BioTherapeutics Corp
(Exact Name of Registrant as Specified in Its Charter)
Cayman Islands | Not Applicable | |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
|
Stealth BioTherapeutics Corp c/o Intertrust Corporate Services (Cayman) Limited One Nexus Way Camana Bay Grand Cayman KY1-9005 Cayman Islands |
Not Applicable | |
(Address of Principal Executive Offices) | (Zip Code) |
2019 Share Incentive Plan
2020 ADS Incentive Plan
(Full Title of the Plan)
Stealth BioTherapeutics Inc.
140 Kendrick Street
Building C-West
Needham, MA 02494
(Name and Address of Agent For Service)
(617) 600-6888
(Telephone Number, Including Area Code, of Agent For Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
|
||||||||
Title of Securities to be Registered |
Amount to be Registered(1) |
Proposed Maximum Offering Price Per Share |
Proposed
Maximum
Offering Price |
Amount of Registration Fee |
||||
Ordinary Shares, $0.0003 par value per share(4) |
14,697,061(2) | $0.146(3) | $2,149,445(3) | $234.50 | ||||
Ordinary Shares, $0.0003 par value per share(4) |
9,526,380(5) | $0.146(3) | $1,393,233(3) | $152.00 | ||||
|
||||||||
|
(1) |
In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
(2) |
Consists of 14,697,061 ordinary shares issuable under the 2019 Share Incentive Plan, as amended, as of January 1, 2021, pursuant to such plans evergreen provision. |
(3) |
Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and Rule 457(h) of the Securities Act of 1933, as amended, and based on the average of the high and low sale prices of the registrants ADSs on the Nasdaq Global Market on February 25, 2021. |
(4) |
American Depositary Shares (ADSs) issuable upon deposit of the ordinary shares registered hereby have been registered under a separate registration statement on Form F-6 (File No. 333-229509), as amended. Each ADS represents 12 ordinary shares. |
(5) |
Consists of 793,865 ADSs, representing 9,526,380 ordinary shares, issuable under the 2020 ADS Incentive Plan, as amended, as of January 1, 2021, pursuant to such plans evergreen provision. |
Statement of Incorporation by Reference
This Registration Statement on Form S-8, relating to the 2019 Share Incentive Plan (the 2019 Plan) and the 2020 ADS Incentive Plan (the 2020 Plan) of Stealth BioTherapeutics Corp (the Registrant) is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8, File No. 333-230452, filed with the Securities and Exchange Commission on March 22, 2019 by the Registrant, relating to the Registrants 2006 Share Incentive Plan and 2019 Plan and (ii) the Registration Statement on Form S-8, File No. 333-237541, filed with the Securities and Exchange Commission on April 2, 2020, relating to the Registrants 2020 Plan, in each case except for Item 8, Exhibits.
Item 8. Exhibits.
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Needham, Massachusetts, on this 26th day of February, 2021.
Stealth BioTherapeutics Corp | ||
By: |
/s/ Irene P. McCarthy |
|
Irene P. McCarthy | ||
Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Stealth BioTherapeutics Corp, hereby severally constitute and appoint Irene P. McCarthy and Henry Hess, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Stealth BioTherapeutics Corp to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date |
||
/s/ Irene P. McCarthy Irene P. McCarthy |
Chief Executive Officer and Director (principal executive officer, principal financial officer and principal accounting officer) | February 26, 2021 | ||
/s/ Francis W. Chen Francis W. Chen, Ph.D. |
Director | February 26, 2021 | ||
/s/ Gerald L. Chan Gerald L. Chan, Sc.D. |
Director | February 26, 2021 | ||
/s/ Kevin F. McLaughlin Kevin F. McLaughlin |
Director | February 26, 2021 | ||
/s/ Eve Slater Eve Slater |
Director | February 26, 2021 | ||
/s/ Louis Lange Louis Lange |
Director | February 26, 2021 | ||
/s/ Edward P. Owens Edward P. Owens |
Director | February 26, 2021 |
STEALTH BIOTHERAPEUTICS INC. | ||
Authorized Representative in the United States | ||
By: |
/s/ Irene P. McCarthy |
|
Name: | Irene P. McCarthy | |
Title: | Chief Executive Officer |
1 Year Stealth BioTherapeutics Chart |
1 Month Stealth BioTherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions